{"id":"ofloxacin-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Lid edema"}]},"_chembl":{"chemblId":"CHEMBL4","moleculeType":"Small molecule","molecularWeight":"361.37"},"_dailymed":{"setId":"4ca27244-ed70-4868-b2d8-8f97c3a52148","title":"OFLOXACIN (OFLOXACIN OPHTHALMIC SOLUTION USP, 0.3%) SOLUTION/ DROPS [SOLA PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to disruption of bacterial DNA synthesis, cell death, and bactericidal activity. The 0.3% ophthalmic formulation is used topically on the eye to treat bacterial infections.","oneSentence":"Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:01.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial corneal ulcers"},{"name":"Ocular infections caused by susceptible gram-positive and gram-negative bacteria"}]},"trialDetails":[{"nctId":"NCT03655665","phase":"PHASE4","title":"Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2019-05-16","conditions":"Otitis Media","enrollment":125},{"nctId":"NCT05657717","phase":"PHASE2, PHASE3","title":"Safety Profile of Applied 100% Manuka Honey in Tympanoplasty","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-07-13","conditions":"Chronic Suppurative Otitis Media, Tympanic Membrane; Wound","enrollment":64},{"nctId":"NCT05605262","phase":"PHASE2, PHASE3","title":"Effects of 100% Medical Grade Manuka Honey on Tympanic Membrane Reconstruction Healing.","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-06-13","conditions":"Otitis Media, Suppurative, Tympanic Membrane Perforation","enrollment":64},{"nctId":"NCT02567825","phase":"NA","title":"Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media","status":"COMPLETED","sponsor":"Alejandro Hoberman","startDate":"2015-11","conditions":"Acute Otitis Media","enrollment":250},{"nctId":"NCT05213156","phase":"PHASE4","title":"Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2019-09-24","conditions":"Dry Eye Disease","enrollment":91},{"nctId":"NCT04213313","phase":"","title":"Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2016-10-01","conditions":"Infectious Keratitis","enrollment":145},{"nctId":"NCT03519516","phase":"PHASE1","title":"Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-01-25","conditions":"Conjunctivitis, Conjunctivitis, Bacterial","enrollment":30},{"nctId":"NCT02540785","phase":"NA","title":"Early Changes Between Lenticule Extraction and Small-Incision Lenticule Extraction","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Myopia, Astigmatism","enrollment":41},{"nctId":"NCT02551796","phase":"NA","title":"Early Changes Among FLEx, LASIK and FS-LASIK","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-09","conditions":"Myopia, Astigmatism","enrollment":75},{"nctId":"NCT00584155","phase":"PHASE1","title":"Protection From Cisplatin Ototoxicity by Lactated Ringers","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2006-07","conditions":"Hearing Loss","enrollment":""},{"nctId":"NCT01573910","phase":"PHASE3","title":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-05","conditions":"Bacterial Conjunctivitis","enrollment":985},{"nctId":"NCT00392275","phase":"PHASE4","title":"Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2002-11","conditions":"Cataract","enrollment":48},{"nctId":"NCT01761071","phase":"PHASE3","title":"Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-01","conditions":"Myopes Who Have Undergone PRK.","enrollment":94},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00781521","phase":"PHASE3","title":"Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Otitis Media","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ofloxacin 0.3%","genericName":"Ofloxacin 0.3%","companyName":"Indiana University School of Medicine","companyId":"indiana-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial corneal ulcers, Ocular infections caused by susceptible gram-positive and gram-negative bacteria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}